Aptose Biosciences shares to delist from Nasdaq as of April 2
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 01 2025
0mins
Delisting Announcement: Aptose Biosciences will be delisted from the Nasdaq Stock Market after failing to meet the equity requirement by the March 31 deadline set by the Nasdaq Hearings Panel.
Future Plans: The company plans to review options, including an appeal, while continuing its business operations and aims to list on a U.S. national Securities Exchange in the future; it remains listed on the TSX under the symbol "APS".
About the author

Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.





